IFNA2 抗体 (Biotin)
Quick Overview for IFNA2 抗体 (Biotin) (ABIN7608267)
抗原
See all IFNA2 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
- 
    - 
                                            原理
- Biotinylated Anti-IFNA2 antibody(1B7), IgG1 Chimeric mAb
- 
                                            纯化方法
- Purified from cell culture supernatant by affinity chromatography
- 
                                            亚型
- IgG1
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- Flow Cyt 1/100
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Lyophilized
- 
                                            缓冲液
- Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 27 % trehalose is added as protectants before lyophilization.
- 
                                            储存条件
- -20 °C,-80 °C
- 
                                            储存方法
- Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -99°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - IFNA2 (Interferon, alpha 2 (IFNA2))
- 
                                            别名
- IFNA2
- 
                                            背景
- This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]
- 
                                            UniProt
- P01563
- 
                                            途径
- JAK/STAT Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C
 抗原
- 
                    
 
                                     
                                     
                                    